HopeStage
Back to all studies
TerminatedNCT03110575

12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

Medication studyAges 18–75United States
The study in practice

Understand this study

Who could participate?

This study is for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.

Listed locations
Phoenix and 31 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: June 20, 2017
Recruitment status
Terminated
Enrollment listed in the registry
190
Sponsor
Tonix Pharmaceuticals, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT03110575
Official title
Show the full official title

A 12-Week Open-Label Extension Study to Evaluate TNX-102 SL Taken Daily at Bedtime in Patients With PTSD

Recruitment & locations

Terminated

Phoenix · Rogers · Beverly Hills

28 more locations
  • Glendale
  • Oakland
  • Oceanside
  • Orange
  • Riverside
  • San Diego
  • Temecula
  • Colorado Springs
  • Jacksonville
  • Lake City
  • Lauderhill
  • Tampa
  • Atlanta
  • New Bedford
  • Flowood
  • Las Vegas
  • Berlin
  • Cedarhurst
  • New York
  • Canton
  • Cincinnati
  • Dayton
  • Oklahoma City
  • Charleston
  • Austin
  • Dallas
  • Houston
  • San Antonio

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Tonix Pharmaceuticals, Inc.

Does this study involve medication?

Yes. The study involves medication, including TNX-102 SL.

Who can participate?

This study is for people with PTSD. Listed age limits: 18 years to 75 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies